About this Event
27 Graves Place, Holland, MI 49423-3617
“From start-up to global commercialization of a medical device to stop postpartum hemorrhage in women in developing regions of the world” by Nathan Bair ’00, Director of Instrument Development, Owl Biomedical, Angel Investor and Start-up Mentor
Nathan Bair will describe his experiences as a co-founder of a startup that developed a medical device that stops postpartum hemorrhage (the #1 cause of death in childbirth). Postpartum hemorrhage is one of the most common complications of birth, requiring pharmacologic treatment in up to 10% of mothers and potentially resulting in emergency intervention such as hysterectomy and blood transfusions. The talk will address the development of the device, the difficulties of raising money, and the challenges of conducting research in Africa, India, and Indonesia. The seminar topics will also include working with the FDA and conducting clinical trials.
Nathan Bair is currently the Director of Instrument Development for Owl Biomedical, and is the founder and Chief Technology Officer at InPress Technologies (Alydia Health). He is also active as an angel investor and mentor to start-up founders. His career focuses on projects that advance disease treatment, with direct impact on aiding patient care. Nathan has learned that women’s health in particular is vastly underserved in the area of medicine – particularly women of color in developing regions of the world. He witnessed the challenges of poverty, access to health care, and environmental degradation related to education and wealth disparities. Nathan is passionate in his belief that great challenges can be met through science, engineering and education. In 2021 Alydia was acquired by Organon a global women’s healthcare company.
0 people are interested in this event